Table 1.

Characteristics of patients with T-malignancies according to genetic subgroups



Total population studied

Subgroup

All HOX11L2 negative

HOX11L2 positive
HOX11-high
SIL-TAL
Other*
Total, N (%)   138 (100)   35 (100)   10 (100)   17 (100)   76 (100)   118 (100)  
Disease, n       
    ALL   127 (92.0)   34 (97.1)   9 (90)   15 (88.2)   69 (90.8)   107 (90.7)  
    Lymphoblastic lymphoma   11 (8.0)   1 (2.9)   1 (10)   2 (11.8)   7 (9.2)   11 (9.3)  
Sex, n       
    Male   102 (73.9)   28 (80)   9 (90)   13 (76.5)   52 (68.4)   87 (73.7)  
    Female   36 (26.1)   7 (21)   1 (10)   4 (23.5)   24 (31.5)   31 (26.3)  
Age at diagnosis, y       
    Median   8   6   5   11   8.5   8  
    Range   0-17   3-13   0-14   1-14   1-17   1-17  
WBC count       
    Less than 50 × 109/L, n   69 (50.0)   22 (62.9)   6 (60)   4 (23.5)   37 (48.7)   54 (45.8)  
    50-99 × 109/L, n   18 (13.0)   5 (14.3)   0 (0)   2 (11.8)   11 (14.5)   19 (16.1)  
    At least 100 × 109/L or greater, n   51 (37.0)   8 (22.9)   4 (40)   11 (64.7)   28 (36.8)   45 (38.1)  
    Median, × 109/L   49   34   29   124   51   58  
    Range, × 109/L   1.9-999.8   3.4-288   9-346   3.6-646   1.9-998   1.9-998  
Mediastinal involvement, n       
    No   14 (10.1)   4 (11.4)   0 (0)   3 (17.6)   7 (9.2)   15 (12.7)  
    Yes   124 (89.9)   31 (88.6)   10 (100)   14 (82.4)   69 (90.8)   103 (87.3)  
    Immunophenotype, n       
    T-lineage (no further specified)   38 (27.5)   11 (31.4%)   1 (10)   5 (29.4)   21 (27.6)   36 (30.5)  
    Early-T   24 [24.0]   2 [8.3]   1 [11.1]   3 [25.0]   18 [32.7]   23 [28.0]  
    Cortical-T   44 [44.0]   16 [66.7]   6 [66.7]   5 [41.7]   17 [30.9]   32 [39.0]  
    Mature-T   32 [32.0]   6 [25.0]   2 [22.2]   4 [33.3]   20 [36.4]   27 [32.9]  
Cytogenetics in ALL patients, n       
    Not done or failure   16 (12.6)   1 (2.9)   0 (0.0)   2 (13.3)   13 (18.8)   16 (15.0)  
    Normal   48 [43.2]   21 [63.6]   5 [55.6]   4 [30.8]   18 [32.1]   33 [36.3]  
    Abnormal
 
63 [56.8]
 
12 [36.4]
 
4 [44.4]
 
9 [69.2]
 
38 [67.9]
 
58 [63.7]
 


Total population studied

Subgroup

All HOX11L2 negative

HOX11L2 positive
HOX11-high
SIL-TAL
Other*
Total, N (%)   138 (100)   35 (100)   10 (100)   17 (100)   76 (100)   118 (100)  
Disease, n       
    ALL   127 (92.0)   34 (97.1)   9 (90)   15 (88.2)   69 (90.8)   107 (90.7)  
    Lymphoblastic lymphoma   11 (8.0)   1 (2.9)   1 (10)   2 (11.8)   7 (9.2)   11 (9.3)  
Sex, n       
    Male   102 (73.9)   28 (80)   9 (90)   13 (76.5)   52 (68.4)   87 (73.7)  
    Female   36 (26.1)   7 (21)   1 (10)   4 (23.5)   24 (31.5)   31 (26.3)  
Age at diagnosis, y       
    Median   8   6   5   11   8.5   8  
    Range   0-17   3-13   0-14   1-14   1-17   1-17  
WBC count       
    Less than 50 × 109/L, n   69 (50.0)   22 (62.9)   6 (60)   4 (23.5)   37 (48.7)   54 (45.8)  
    50-99 × 109/L, n   18 (13.0)   5 (14.3)   0 (0)   2 (11.8)   11 (14.5)   19 (16.1)  
    At least 100 × 109/L or greater, n   51 (37.0)   8 (22.9)   4 (40)   11 (64.7)   28 (36.8)   45 (38.1)  
    Median, × 109/L   49   34   29   124   51   58  
    Range, × 109/L   1.9-999.8   3.4-288   9-346   3.6-646   1.9-998   1.9-998  
Mediastinal involvement, n       
    No   14 (10.1)   4 (11.4)   0 (0)   3 (17.6)   7 (9.2)   15 (12.7)  
    Yes   124 (89.9)   31 (88.6)   10 (100)   14 (82.4)   69 (90.8)   103 (87.3)  
    Immunophenotype, n       
    T-lineage (no further specified)   38 (27.5)   11 (31.4%)   1 (10)   5 (29.4)   21 (27.6)   36 (30.5)  
    Early-T   24 [24.0]   2 [8.3]   1 [11.1]   3 [25.0]   18 [32.7]   23 [28.0]  
    Cortical-T   44 [44.0]   16 [66.7]   6 [66.7]   5 [41.7]   17 [30.9]   32 [39.0]  
    Mature-T   32 [32.0]   6 [25.0]   2 [22.2]   4 [33.3]   20 [36.4]   27 [32.9]  
Cytogenetics in ALL patients, n       
    Not done or failure   16 (12.6)   1 (2.9)   0 (0.0)   2 (13.3)   13 (18.8)   16 (15.0)  
    Normal   48 [43.2]   21 [63.6]   5 [55.6]   4 [30.8]   18 [32.1]   33 [36.3]  
    Abnormal
 
63 [56.8]
 
12 [36.4]
 
4 [44.4]
 
9 [69.2]
 
38 [67.9]
 
58 [63.7]
 

Numbers in parentheses and brackets are percentages.

*

Negative for 3 genetic markers.

This group included 118 patients: 10 patients with HOX11-high, 17 patients positive for SIL-TAL, 76 patients with other, and 15 additional patients who tested negative for HOX11L2 and not tested for HOX11 and SIL-TAL status.

Percentages between [] were calculated taking into account only documented cases

or Create an Account

Close Modal
Close Modal